Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational targeted radiotherapeutic. The Ovarian Cancer Research Alliance sponsored the symposium, held October 16–18, 2026, in Philadelphia. In two mouse models of aggressive epithelial ovarian cancer, treatment with rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL), the active agent in REYOBIQ, was associated with tumor injury and changes in the tumor microenvironment. Combination treatment with anti-PD-1 checkpoint blockade also showed improved antitumor activity.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.